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ABSTRACT 8 
The seed of industrial hemp is an underexploited protein source. In view of a possible use in 9 
functional foods, a hempseed protein concentrate was hydrolyzed with pepsin, trypsin, 10 
pancreatin, or a mixture of these enzymes. A detailed peptidomic analysis using data-dependent 11 
acquisition showed that the numbers of peptides identified ranged from 90 belonging to 33 12 
parent proteins in the peptic hydrolysate to 9 belonging to 6 proteins in the pancreatin digest. 13 
The peptic and tryptic hydrolysates resulted to be the most efficient inhibitors of 3-14 
hydroxymethyl-coenzyme A reductase activity, when tested on the catalytic domain of the 15 
enzyme. Using the open access tools PeptideRanker and BIOPEP, a list of potentially bioactive 16 
peptides was generated: the alleged activities included the antioxidant property, the glucose 17 
uptake stimulating activity, the inhibition of dipeptidyl peptidase-IV (DPP-IV) and of 18 
angiotensin converting enzyme I (ACE). 19 
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INTRODUCTION 25 
Currently, there is a growing interest for the production of food protein hydrolysates containing 26 
bioactive peptides for potential applications in functional foods. So far, much research has been 27 
focused on the use of animal proteins (milk, egg, fish, meat) as raw materials for the production 28 
of such bioactive peptides.1 However, edible plants and mainly their seeds represent cheap and 29 
environmentally sustainable protein sources currently investigated for the same purpose.2  30 
Certainly, a complete information on peptide sequences is crucially relevant in order to elucidate 31 
the correlation between the composition of such hydrolysates and the observed biological activities 32 
and to elucidate the molecular mechanisms involved. This knowledge is, therefore, a key factor in 33 
the development of applications in nutraceuticals and functional foods. In fact, the specific 34 
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bioactivity of food peptides against various molecular targets depends on their structural 35 
properties, such as amino acid composition, length and physicochemical characteristics of the 36 
amino acid side chains, as well as their bulkiness, hydrophobicity, and charge.3 Given a single 37 
starting material, different peptide profiles may be achieved under varying hydrolytic conditions, 38 
since enzymatic activity is a function of structural characteristics of the substrate on which the 39 
proteases act.4 To date, the characterization of the relative similarities and differences between 40 
such peptide profiles remains largely unstudied. In this context, the advent of peptidomics based 41 
on advanced analytical techniques, in particular mass spectrometry, allows to elucidate the full 42 
components present in a specific peptide mixture. Indeed, continued advances in tandem MS 43 
technologies provide today more and more accurate identifications and quantifications of such 44 
peptides.5 Accordingly, this technology has attracted the attention of food scientists and 45 
nutritionists as a promising approach for the characterization of food protein hydrolysates.6-8  46 
While proteomics usually comprises molecular weights from approx. 700 to 3000 Da with a 47 
dynamic range of twelve orders of magnitude, peptidomics certainly spans over a greater peptide 48 
length distribution showing instead a similar dynamic range.8 Moreover, the high concentration of 49 
low molecular weight peptides in food hydrolysates is undoubtedly an analytical challenge to 50 
peptidomic analysis, and research in this area is yielding significant results especially for the 51 
identification of small peptides.  52 
The seed of industrial hemp, i.e. the non-drug cultivars of Cannabis sativa, is certainly an 53 
underexploited protein-rich seed.9 Hempseed proteins are an excellent natural source of highly 54 
digestible amino acids when compared to other protein sources, such as borage meal, canola meal, 55 
and heated canola meal.10, 11 Interestingly, recent investigations have demonstrated that peptides 56 
produced by enzymatic hydrolysis of hempseed proteins provide several biological activities, 57 
including the antihypertensive one12, 13 and antioxidant one.12, 14, 15  58 
In addition, a few literature evidences indicate that the inclusion of hempseed protein in the diet 59 
of suitable animal models modulates their lipid profile in a favorable way.16-18 Since proteins are 60 
hydrolyzed during digestion, the activity may be due to specific peptides encrypted in the protein 61 
sequences that are released by digestion and absorbed at intestinal level. This has stimulated our 62 
interest for assessing whether the enzyme selection and technical conditions may modulate the 63 
hypocholesterolemic properties of hempseed peptides.19 In fact, the bioactivity of food protein 64 
hydrolysates depends strictly on these parameters.20  65 
Based on these considerations, the overall objective of the present study was to compare the 66 
efficiency of some enzymes and/or enzyme combinations in the production of bioactive protein 67 
hydrolysates from hempseed. In details, the specific objectives were: (i) the optimization of the 68 
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release of the peptides from hempseed protein using different enzymes; (ii) the identification and 69 
characterization of each hydrolysate by a shotgun MS based approach; iii) the evaluation of the 70 
inhibitory activity of each hydrolysate on 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase 71 
(HMGCoAR), a key enzyme in cholesterol metabolism; and (iv) the prediction of additional 72 
biological activities using in silico bioinformatics tools.  73 
 74 
MATERIALS AND METHODS 75 
Reagents. All chemicals and reagents were of analytical grade.  LC-grade H2O (18 MΩ cm) was 76 
prepared with a Milli-Q H2O purification system (Millipore, Bedford, MA, USA). Acetonitrile 77 
(ACN), tris(hydroxymethyl)aminomethane (Tris-HCl), hydrochloric acid (HCl), ammonium 78 
bicarbonate, and HMGCoAR assay Kit were provided by Sigma-Aldrich (St. Louis, MO, USA). 79 
Pepsin from porcine gastric mucosa (P7012, lyophilized powder, ≥ 2,500 units/mg protein), trypsin 80 
from bovine pancreas (T1426, lyophilized powder, ≥ 10,000 units/mg protein), and pancreatin 81 
from porcin pancreas (P1625, powder, 3 x ≥ USP specification) were from Sigma-Aldrich (St. 82 
Louis, MO, USA). Bovine serum albumin (BSA) and β-mercaptoethanol were from Thermo Fisher 83 
Scientific (Life Techonoly, Milan Italy). Mini-Protean apparatus, precision plus protein standards, 84 
Bradford reagent and Coomassie Blue G-250 were purchased from Bio-Rad (Hercules, CA, USA).  85 
 86 
Protein concentrate preparation. The seeds of the species C. sativa (cultivar Futura) were 87 
provided by the Institute of Agricultural Biology and Biotechnology, CNR (Milan, Italy). The 88 
hempseed protein concentrate (HPC) was prepared applying the method described previously with 89 
some modifications.21 Briefly, 2 g of defatted hempseed flour were homogenized with 15 mL of 90 
100 mM Tris-HCl/0.5 M NaCl buffer, pH 8.0. The extraction was performed in batch at 4 °C 91 
overnight. The solid residue was eliminated by centrifugation at 5,800 g for 30 min at 4 °C and the 92 
supernatant was dialyzed against 100 mM Tris-HCl buffer, pH 8.0 for 36 h at 4 °C. The protein 93 
content of HPC, assessed according to the Bradford method using BSA as standard, was 15.4 94 
mg/mL.  95 
 96 
Preparation of the hempseed protein hydrolysates. The HPC, dissolved in 100 mM Tris-97 
HCl/0.5 M NaCl buffer pH 8.0, was hydrolyzed using three single enzymes: i.e. pepsin, trypsin, 98 
pancreatin or, in order to mimic the gastrointestinal digestion, a combination of the same enzymes. 99 
The peptic hydrolysis was performed adjusting the pH to 2 by adding 1 M HCl to the HPC. The 100 
enzyme solution (4 mg/mL in NaCl 30 mM) was added in a 1:50 enzyme/hempseed protein ratio 101 
(w/w). The mixture was incubated for 16 h and the enzyme inactivated changing the pH to 7 by 102 
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adding 1 M NaOH. Tryptic and pancreatic hydrolysis was performed directly in the buffer solution 103 
adding trypsin (4 mg/mL in HCl 1 mM) and pancreatin (4 mg/mL in H2O) in a 1:50 enzyme/HPC 104 
ratio (w/w). After 16 h incubation, the digestion was stopped changing the pH to 3 by adding 1 M 105 
HCl. The simulated gastrointestinal digestion was initiated by the addition of pepsin [1:20 (w/w) 106 
enzyme/hempseed protein ratio] stirring the mixture for 2 h at pH 2. After that, the reaction mixture 107 
was adjusted to pH 8.5 with 1 M NaOH followed by the addition of a mixture of trypsin and 108 
pancreatin, each at a 1:25 enzyme/HPC (w/w) ratio. The mixture was incubated at 37 °C for 4 h. 109 
The enzymatic reaction was terminated by adjusting the mixture to pH 3 with 1 M HCl. Each 110 
digestion was stopped by holding at 95 °C for 10 min to ensure a complete inactivation of residual 111 
enzyme activity.  112 
All digestion processes were performed at 37 °C and all obtained hydrolysates were purified 113 
separating the undigested proteins, the high molecular-weight polypeptides and the intact enzymes 114 
by ultrafiltration through membranes with a 3-kDa molecular weight cut-off (MWCO) (Millipore, 115 
USA) at 12,000 g for 30 min at 4 °C. Finally, the permeated peptides were collected and stored at 116 
-20 °C until used in further experiments.  117 
 118 
Evaluation of the percent peptide yield and DH of the hydrolysates. The peptide concentration 119 
(µg/µL) of each hydrolysate was determined according to a literature method,22 which is based on 120 
chelating the peptide bonds by Cu(II) in alkaline media and monitoring the change of absorbance 121 
at 330 nm according to Lammi et al., 2016.23 The percent peptide yield from the HPC was 122 
determined as the ratio between peptide concentration and the protein concentration of the non-123 
hydrolyzed HPC, estimated by Bradford assay. The degree of hydrolysis was determined by the 124 
OPA assay, according to Nielsen et al., 200124 with some modifications. This assay is based on 125 
the formation of an adduct between the α-amino groups of peptides and the OPA reagent. The 126 
assay consisted of mixing 200 µL of OPA reagent with 26.6 µL of hydrolysates. After 1.5 min of 127 
incubation at 25 °C, the absorbance was measured at 340 nm using the Synergy H1 fluorescent 128 
plate reader (Biotek, Bad Friedrichshall, Germany).  129 
 130 
 131 
Tricine SDS-PAGE Separation. To monitor the efficacy of  hydrolysis, Tris-Tricine SDS-PAGE 132 
was used following a literature method.25 A 16.0% resolving gel using 40% acrylamide/bis 133 
solution (19:1) and 6 M urea was prepared and overlaid with 5% stacking gel. A fixed volume 134 
(500 µL) of each hydrolysate was dried and dissolved in 15 µL of 2X loading buffer containing 135 
SDS, β-mercaptoethanol, glycerol and Coomassie G-250 stain. The mixture was heated in a boiling 136 
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water bath for 5 min, vortexed for 30 sec, and allowed to cool to room temperature. All the 15 µL 137 
of the sample were loaded onto the gel. A mixture of proteins (range 26.7 kDa -1.4 kDa, Biorad) 138 
was used as a broad range MW marker. The cathodic compartment were filled with Tris–Tricine 139 
buffer, pH 8.3, containing 0.1%, m/v SDS, whereas the anodic compartment was filled with Tris-140 
HCl, pH 8.9. Electrophoreses were run on a Mini-Protean II Cell at 100 V until the dye front 141 
reached the gel bottom. The resolved protein bands were stained by immersing the gel in a solution 142 
containing 45% methanol, 10% glacial acetic acid, and 0.25% Coomassie Brilliant Blue R-250 for 143 
1.5 h. To visualize the bands, the gel was destained in a solution containing 45% methanol and 144 
10% glacial acetic acid until they were clearly visible. 145 
 146 
MS/MS peptide profiling. The peptide solutions (100 µL) were desalted on SepPak C18 cartridge 147 
(Thermo Fisher Scientific, Life Technology, Milan Italy) conditioned with MeOH and rinsed with 148 
0.1% FA. Peptides were eluted from the SPE column with 280 μL ACN:H2O (80:20, v/v) 149 
containing 0.1% FA and then dried in a Speed-Vac (Martin Christ). Each sample was reconstituted 150 
with 20 μL of a solution of 2% ACN, 0.1% FA, properly diluted, and analyzed on a SL IT mass 151 
spectrometer interfaced with a HPLC-Chip Cube source (Agilent Technologies, Palo Alto, CA, 152 
USA). Each sample was loaded onto a 40 nL enrichment column (Zorbax 300SB-C18, 5 µm pore 153 
size), and separated onto a 43 mm × 75 µm analytical column packed (Zorbax 300SB-C18, 5 µm 154 
pore size). Separation was carried out in gradient mode at a flowrate of 300 nL/min. The LC 155 
solvent A was 95% water, 5% ACN, 0.1% formic acid; solvent B was 5% water, 95% ACN, 0.1% 156 
formic acid. The nano pump gradient program was as follows: 5% solvent B (0 min), 80% solvent 157 
B (0–40 min), 95% solvent B (40–45 min), and back to 5% in 5 min. A reconditioning at the initial 158 
chromatographic conditions was conducted for 5 minutes. The drying gas temperature was 300 159 
°C, flow rate 3 L/min (nitrogen). Data acquisition occurred in positive ionization mode. Capillary 160 
voltage was −1950 V, with endplate offset −500 V. Full scan mass spectra were acquired in the 161 
mass range from m/z 300 to 2000 Da. LC-MS/MS analysis was performed in data-dependent 162 
acquisition AutoMS(n) mode. In order to increase the number of identified peptides, three 163 
technical replicates (LC–MS/MS runs) were run for each of the three experimental replicates. 164 
 165 
Database searching, protein identification and validation. The MS/MS data were analyzed by 166 
Spectrum Mill Proteomics Workbench (Rev B.04.00, Agilent), consulting the C. sativa (531 167 
sequences) protein sequences database downloaded from the National Center for Biotechnology 168 
Information (NCBI). The enzymes selected were pepsin and trypsin for the analysis of the peptic 169 
and tryptic hydrolysates, respectively; whereas none specific cleavage was selected for analyzing 170 
6 
 
the pancreatic and co-digested hydrolysates. Two missed cleavages were allowed to each enzyme 171 
used; peptide mass tolerance was set to 1.2 Da and fragment mass tolerance to 0.9 Da. For quality 172 
assignment, a sequence tag lengths > 4 was used. Threshold used for peptide identification score 173 
≥ 6; Scored Peak Intensity SPI% ≥ 70%; autovalidation strategy both in peptide mode and in 174 
protein polishing mode was performed using FDR cut-off ≤ 1.2 %. Protein abundance was 175 
performed at protein level using Total Protein Spectral Intensity (TPSI) based on the summation 176 
of peptide intensities, calculated from extracted ion chromatograms from each precursor ions.  177 
 178 
Amino acid composition. The amino acid compositions of the hempseed hydrolysates and the 179 
isoelectric points (pI) were determined using ProtParam tool (http://web.expasy.org/protparam/).26 180 
Hierarchical clustering analysis (HCA) and its visualization were performed using Cluster 3.0 and 181 
Java TreeView, respectively. HCA allows the presentation of cluster results in a dendrogram, 182 
where the similarity among the samples is determined from the value on the distance axis at which 183 
they join in a single cluster (the smaller the distance, the more similar the sample). Euclidean 184 
distance was used to calculate the matrix of all samples. The complete linkage method was then 185 
used in the assignment of clusters.  186 
 187 
HMGCoAR activity assay. The HMGCoAR inhibitory activity of each hydrolysate was 188 
evaluated using a commercial assay Kit providing HMGCoAR (catalytic domain), NADPH, assay 189 
buffer, and substrate solution. The experiments were carried out at 37 °C following the 190 
manufacturer’s instructions. Each reaction (200 μL) was prepared by adding the reagents in the 191 
following order: 1X assay buffer;  0.2, 0.3, 0.5, and 1.0 mg/mL of co-digested peptides,  with 1.0, 192 
and 2.0 mg/mL of the peptides digested with pancreatin, 0.1, 0.25, 0.35, 0.5, and 1.0 mg/mL of the 193 
peptides digested with pepsin, or 0.2, 0.5, and 1.0 mg/mL of the peptides digested with trypsin or 194 
vehicle (C); NADPH (4 μL); substrate solution (12 μL); and finally HMGCoAR (2 μL). 195 
Subsequently, the samples were mixed, and the absorbance at 340 nm was read by a microplate 196 
reader (Synergy H1 from Biotek, Bad Friedrichshall, Germany) at 0 and 10 min. The HMGCoA-197 
dependent oxidation of NADPH and the inhibition properties of hempseed peptides were measured 198 
by the absorbance reduction, which is directly proportional to the enzyme activity.  199 
 200 
Profile of potential biological activities and peptide ranking. The potential bioactivities of 201 
hempseed peptides were predicted using the open access tool PeptideRanker 202 
(http://bioware.ucd.ie/compass/biowareweb/),27  a web-based tool used to predict the probability 203 
of biological activity of peptide sequences. Using N-to-1 neural network probability, 204 
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PeptideRanker provides peptide scores in the range of 0–1. The maximum scores indicate the most 205 
active peptides, whereas the minimum scores denote the least active peptides. Here, only those 206 
peptides with a score higher than 0.6 were considered as potentially “bioactive”. Subsequently, the 207 
lists of best-ranked peptides were submitted to the web-available database BIOPEP 208 
(http://www.uwm.edu.pl/biochemia/index.php/pl/biopep/). 209 
 210 
Statistical analysis in the HMGCoAR activity assay. Statistical analyses were carried out by 211 
One-way ANOVA (Graphpad Prism 6) followed by Dunnett’s test. Values were expressed as 212 
means ± SD; P-values < 0.05 were considered to be significant.  213 
 214 
 215 
RESULTS 216 
Hydrolysis trend, yield, and DH of hempseed hydrolysates. In order to produce protein 217 
hydrolysates endowed with potential biological activities, HPC was digested using one enzyme, 218 
i.e. pepsin, trypsin, or pancreatin, or a mixture of the same enzymes in order to mimic the 219 
gastrointestinal digestion. The highest peptide yield was observed for the pancreatic hydrolysate 220 
(43%), followed by the tryptic hydrolysate (24.6%), the co-digested hydrolysate (18.2%) and the 221 
peptic one (16%). The DH values were 19.7% for peptic hydrolysate, 46.6% for tryptic, 47.5% for 222 
pancreatic, and 34% for codigested. These results indicate a direct correlation between the peptide 223 
yields and the DH values, the trends across all hydrolysates are comparable.  224 
In order to monitor the efficiency of the hydrolysis, a tricine-SDS-PAGE was used to resolve the 225 
peptide pool composition of each hydrolysates. Figure 1 shows the profile of the molecular weight 226 
distribution at the end of digestion. The peptic hydrolysate showed many continuous, intense and 227 
unresolved bands in the range from 3.5 to 26.6 kDa, the co-digested hydrolysate displayed another 228 
band-rich profile, whereas the tryptic and pancreatic presented only small bands between 6.5 and 229 
26.6 kDa. The absence of intense bands indicated that these hydrolysates contained mostly very 230 
short peptides (MW smaller than 3.5 kDa) that had diffused through the gel. The results of the 231 
percent peptide yields and DH were in agreement with these findings: in fact, consistently, yields 232 
and DH were larger when the bands were more difficult to visualize on the gels.  233 
 234 
Chemical characterization of the protein hydrolysates. The characterization of the four 235 
hydrolysates was carried out by HPLC-Chip MS/MS analysis. The results are summarized in 236 
Table 1S (Supplementary materials), which reports the identified peptides according to their 237 
parent proteins. The peptic hydrolysate was the richest both in terms of identified peptides and 238 
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proteins. In fact, it was possible to detect 90 peptides belonging to 33 C. sativa proteins, whereas 239 
in the codigested sample 62 peptides belonging to 25 proteins were identified. In the tryptic digest, 240 
it was possible to detect 25 peptides accounting for 6 proteins, while only 9 peptides deriving from 241 
6 proteins were identified in the pancreatic hydrolysate. Therefore, the composition in terms of 242 
proteins and peptides is very specific for each hydrolysate. Figure 2A shows the percent 243 
distribution of the peptides deriving from specific parent proteins in each hydrolysate. The peptic 244 
hydrolysate contained peptides derived from numerous proteins, with a small prevalence of the 245 
two isoforms of Edestin (6% from Edestin 1 and 6% from Edestin 2), as well as DNA-directed 246 
RNA polymerase subunit beta (6%) and Protein Ycf2 (6%). The percentage of peptides deriving 247 
from Edestin increased greatly in the tryptic hydrolysate (40% from Edestin 1 and 24% from 248 
Edestin 2). Phenylalanine ammonia-lyase and Ribulose 1,5-bisphosphate carboxylase/oxygenase 249 
were instead the most abundant parent proteins in the pancreatic hydrolysate, accounting for 34% 250 
and 22%, respectively. On the contrary, Photosystem I P700 chlorophyll (10%), Edestin 2 (8%), 251 
NADH-ubiquinone oxidoreductase (6%), and 4-coumarate:CoA ligase (6%) were the parent 252 
proteins of most peptides in the co-digested hydrolysate. The Venn diagram (Figure 2B) highlights 253 
the distribution of the parent proteins among the hydrolysates. Only 13 proteins are common to 254 
the peptic and the co-digested hydrolysates, whereas none protein is shared by all hydrolysates. 255 
These results suggest a very high selectivity of the hydrolytic processes that produced peptide 256 
mixtures with different compositions.  257 
Based on MS/MS results, the clustering of the molecular weights (MW) distribution of the peptides 258 
released after HPC digestion is reported in Figure 3A. Pepsin hydrolysis produced a high number 259 
of peptides that fall into the ranges of 1000-1500 and 2000-2500 Da, whereas the simulated 260 
gastrointestinal digestion yielded predominantly peptides in the 1500-2000 Da range. Hierarchical 261 
clustering analysis (HCA) was applied to classify all samples according to their amino acid 262 
composition (AAC) as reported in Figure 3B. The tryptic, peptic, and co-digested hydrolysates 263 
showed a similar AAC, whereas the pancreatic mixture displayed a different AAC. The amino acid 264 
similarity among all hydrolysates is the driven factory on which the clusters are built. Each step in 265 
the clustering process is illustrated by a joint of the tree. Glu, Gly, Pro, Phe, Val, and Try are 266 
frequently occurring in the peptic, tryptic, and co-digested hydrolysates, whereas they are poorly 267 
expressed in the pancreatic mixture. On the contrary, Met, Arg, Ala, and Cys were the most 268 
abundant amino acid residues in the pancreatic mixture.  269 
 270 
Inhibitory effects of the hydrolysates on the HMGCoAR activity. In order to evaluate 271 
experimentally the ability of the different hydrolysates to inhibit the activity of HMGCoAR, 23 272 
9 
 
an in vitro assay was performed using the purified catalytic domain of this enzyme. Peptide 273 
concentrations ranging from 0.2 to 2.0 mg/mL were tested. Figure 4 shows that, after 274 
incubation with the peptic hydrolysate (0.25, 0.5, and 1.0 mg/mL), the HMGCoAR activity 275 
was inhibited by 24.5 ± 1.7% (p<0.001), 61.1 ± 0.7% (p<0.001), and 80.0 ± 4.0% (p<0.001), 276 
respectively, versus the control. After the incubation with the tryptic hydrolysate (0.2, 0.5, and 277 
1 mg/mL), the HMGCoAR activity was inhibited by 24.6 ± 4.6% (p<0.05), 58.4 ± 1.1% 278 
(p<0.001), 93.3 ± 9.3% (p<0.001), respectively, versus the control. After incubation with the 279 
co-digested hydrolysate (0.2, 0.5, and 1.0 mg/mL), the HMGCoAR activity was inhibited by 280 
16.2 ± 12.6% (p<0.01), 50.6 ± 2.3% (p<0.001), 47.4 ± 1.5% (p<0.001). Finally, after incubation 281 
with the pancreatic hydrolysate the HMGCoAR activity was not significantly inhibited at 1.0 282 
mg/mL, whereas a moderate but significant inhibition by 11.7 ± 6.4% (p<0.05) was observed 283 
at 2.0 mg/mL.  284 
 285 
Peptide ranking, protein abundance and bioactivity searching. In order to extend the 286 
investigation to other potential bioactivities, the peptidome maps were ranked by the tool 287 
PeptideRanker. At the end of this process, only those peptides showing score values higher than 288 
0.6 were considered as potentially bioactive. The data reported in Table 1 demonstrate that there 289 
is not any correlation between high-scored peptides and the total protein spectral intensity (TPSI) 290 
of the proteins from which they are released. In particular, as shown in Figure 5, a great number 291 
of potentially bioactive peptides belong to less abundant proteins. For example, QIQFEGFCRF 292 
(score 0.92) derives from DNA-directed RNA polymerase subunit beta, which is one of the least 293 
abundant proteins detected in the hydrolysates. On the contrary, only one peptide derived from 294 
Edestin 2, DIFNPRGG (score 0.74), was supposed to be bioactive.  295 
In order to hypothesize their possible bioactivities, the best scored peptides were submitted to 296 
BIOPEP search (Table 1). The alleged biological activities included the inhibition of dipeptidyl 297 
peptidase-IV (DPP-IV) and of angiotensin converting enzyme I (ACE), the antioxidant property, 298 
and the glucose uptake stimulating activity. Most bioactive peptides were detected in the 299 
hydrolysates deriving from the peptic and/or the simulated gastrointestinal digestion. Following 300 
the bioinformatic prediction, bioactivities are prevalently provided by short sequences of two or 301 
three amino acids included in their structures.  302 
 303 
DISCUSSION 304 
The first objective of the study was the characterization of the composition of the four 305 
hydrolysates, an important step in the pathway to evaluate their potential use as functional 306 
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ingredients. Having this final goal, all enzymatic digestions were performed avoiding the use of 307 
reducing and alkylating agents in order to produce, as far as possible, unmodified and natural 308 
peptides. This choice of course partially impaired the hydrolytic efficiency of the enzymes.  309 
All employed enzymes were endopeptidases that, with the exception of trypsin, randomly 310 
hydrolyze peptide bonds within the protein sequences, producing peptides differing in amino acid 311 
sequences and sizes. The resulting hydrolysates were diverse in terms of composition and percent 312 
yield of peptides. Pancreatin gave the highest percent yield: this may be attributed to the endo- and 313 
exo-peptidase activities of this enzyme, which increases protein digestion through hydrolysis of 314 
more peptide bonds, when compared to enzymes only endowed with an endopeptidase activity.28 315 
Another high percent yield was observed with trypsin, even if this enzyme is well known for the 316 
high selectivity and specificity in site cutting recognition. A higher peptide yield is the expected 317 
outcome for increased protein breakdown and a marker of the hydrolytic process efficacy. The 318 
consequence of the high hydrolytic efficiency of these enzymes was the relatively small number 319 
of peptides that were identified in their hydrolysates, probably due to an extensive production of 320 
very short peptides, i.e. di-, tri- and tetra peptides, which are difficult to detect using a data-321 
dependent shotgun approach.  322 
The identified peptides ranged from 7 to 29 amino acid residues, i.e. between 747 Da and 3211 323 
Da, in agreement with the ultrafiltration separation that had been performed with a cut-off of 3 324 
kDa. These values correspond to peptides slightly longer than those reported in other studies after 325 
similar digestions of various animal proteins.29 Possibly, this might be explained by the protease 326 
inhibitors present in most plant seeds. In addition, the missing reduction and alkylation of the 327 
disulfide bonds reduced the proteolytic activity of each enzyme resulting in longer peptides.   328 
In order to investigate the different features of the hydrolysates, the HCA of the AAC of all 329 
identified peptides was employed combining the heat map with a dendrogram. The clustering 330 
provides the basis for guiding reasonable enzyme selection in order to produce hydrolysates 331 
endowed of specific chemicals features. As shown by Figure 3B, peptic and co-digested 332 
hydrolysates form two very close clusters according to their amino acid similarity. The AAC of 333 
the tryptic hydrolysate has also some similarity with the peptic and co-digested hydrolysates, but 334 
it falls at a wider distance. On the contrary, the pancreatic hydrolysate is well separated from the 335 
others. The peptic and codigested clusters are near, possibly the effects of pepsin prevails since 336 
this enzyme is the first applied in the codigestion. The tryptic cluster falls at a certain distance, 337 
since its cut sites are different from those recognized by pepsin. Finally, the pancreatic one is the 338 
most distant, since in this case the peptide hydrolysate is generated either by endo- or exopeptidase 339 
action. 340 
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Apparently, their substantial structural diversities reflect also their different capability of inhibiting 341 
the activity of HMGCoAR, a key enzyme in the synthesis of endogenous cholesterol and the main 342 
target of statins, which interact with this enzyme as competitive inhibitors.30 The experiments 343 
performed using the purified catalytic domain of this enzyme showed that the tryptic and peptic 344 
hydrolysates were the best inhibitors (Figure 4), whereas the pancreatin hydrolysate was the least 345 
active, in line with the clustering provided by the HCA analysis. The pancreatic hydrolysate 346 
contains numerous residues of hydrophilic amino acids, such as Glu, Ser, Arg, and Lys, whereas 347 
it is completely devoid of Pro and Val, which are abundant in the other hydrolysates. This may be 348 
related to a synergistic effect of the hydrophobic peptides present in the mixtures, since the 349 
hypocholesterolemic effect is correlated to an increased hydrophobicity.31  350 
In a previous paper, we have investigated the interaction of some soy peptides with the catalytic 351 
domain of HMGCoAR using in silico modeling studies.32 Medium size peptides, containing 8-10 352 
amino acid residues and characterized by a hydrophobic N-terminus and a negatively charged C-353 
terminus, appeared to be particularly favorable for interacting with HMGCoAR. The negatively 354 
charged C-terminal portion is primarily involved in the inhibition by mimicking most of the polar 355 
interactions that are clearly seen also in statins,32 whereas the hydrophobic N-terminal portion is 356 
inserted in a deeper and rather polar sub-pocket that corresponds roughly to that harboring the 357 
NADPH cofactor. In fact, HMGCoAR contains a second relevant domain that is capable of 358 
accepting NADPH: a peptide that prevents this binding impairs the catalytic activity of the 359 
enzyme.32  360 
In order to predict other potential activities, it was decided to use cost effective and time-saving 361 
computer simulated approaches, such as PeptideRanker and BIOPEP. It is important, however, to 362 
underline that these tools take into consideration only some possible biological activities, 363 
excluding for example the inhibition of HMGCoAR. At the end of the procedure, 22 peptides were 364 
postulated to be bioactive. In agreement with the features of BIOPEP, the main proposed activities 365 
were the inhibition of dipeptidyl peptidase-IV (DPP-IV) and of angiotensin converting enzyme I 366 
(ACE), the antioxidant properties, and the glucose uptake stimulating activity. The forecasted 367 
activities are linked to specific short sequences, mostly composed by two or three amino acid 368 
residues, encrypted in their sequences. Specifically, PWT, WPL, and VKV provide antioxidant 369 
activities, which could depend on the presence of substantial amounts of hydrophobic, branched-370 
chain, or aromatic amino acid residues. The hydrophobicity is also important to enhance their 371 
permeability into the target organs through hydrophobic associations with the cell membrane lipid 372 
bilayer, promoting the achievement of potent antioxidant effects.33 In the meanwhile, the 373 
compresence of hydrophobic or aromatic amino acids at the C-terminus as well as of hydrophobic 374 
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and negative ionizable functions (Thr, Glu, Asp, Ser, Met) positively contributes to an effective 375 
ACE inhibition.1, 34, 35 Specifically, the sequences LSP, FEP, and IAE fall in this category. 376 
However, also branched-chain aliphatic amino acids at the C-terminus as well as hydrophobic 377 
amino acids at the N-terminus, such as IFL, LLP, AVL, LLF, contribute to high ACE-inhibitory 378 
activities.28, 36 Finally, also the small sequence GP is expected to provide bioavailability and ACE-379 
inhibitory activity owing to its short sequence, hydrophobicity, and theoretical stability to pepsin 380 
and trypsin cleavage.37 The ACE inhibitory activity as well as the antioxidant activity of hempseed 381 
hydrolysates are confirmed experimentally by literature.28  382 
Another proposed activity is the inhibition of DPP-IV. This enzyme is a new molecular target 383 
correlated with the development of type 2 diabetes.38 The peptides capable of inhibit the DPP-IV 384 
activity have in general a hydrophobic character and a length from 2 to 8 amino acids. Very often, 385 
they contain a Pro residue in their sequence located at the first, second or third or fourth N-terminal 386 
position, which is flanked by Leu, Val, Phe, Ala or Gly.39, 40 A paper has investigated the DPP-IV 387 
inhibitory activity of hempseed protein hydrolysates obtained treating a HPC with different 388 
enzymes obtaining a first indication of a moderate activity also on this enzyme.41  389 
In conclusion, it seems possible to affirm that there are good prospective that hempseed 390 
hydrolysates may be used as multipurpose ingredients in functional foods. Of course, when 391 
discussing the bioactivities of food peptides an open issue remains their bioavailability. In case of 392 
hempseed peptides, this problem is still to be taken into consideration. However, it is useful to 393 
remind that different authors have confirmed the bioavailability of peptides deriving from other 394 
food proteins. 23, 42-44 395 
 396 
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Captions of Figures 544 
 545 
Figure 1. Tricine-SDS-PAGE of hempseed protein hydrolysates. M (marker) 26.6-3.5 kDa. 546 
Pep, Tryp, Panc, Cod represent the four hydrolysates.    547 
 548 
Figure 2. A) Percent distribution of identified peptides according to their parent proteins. B) 549 
Venn diagrams of the total number of identified proteins in each hydrolysate.  550 
 551 
Figure 3. A) MW distribution (in Da) of the identified peptides in each hydrolysate. B) 552 
Hierarchical clustering analysis (HCA) with dendrogram of amino acid data set composition 553 
of each hydrolysate. 554 
 555 
Figure 4. Effect of the hydrolysates on the catalytic domain of HMGCoAR. Bars indicate the 556 
effects of each hydrolysate on the HMGCoAR activity at the following concentrations: (A) 557 
peptic hydrolysate (0.1, 0.25, 0.35, 0.5, and 1.0 mg/mL); (B) tryptic hydrolysate (0.2, 0.5, and 558 
1 mg/mL); (C) pancreatic hydrolysate (1.0, 2.0 mg/mL); (D) co-digested hydrolysate (0.2, 0.5, 559 
and 1.0 mg/mL). HMGCoAR, physiologically, catalyzes the four-electron reduction of HMG-560 
CoA to coenzyme A (CoA) and mevalonate (HMG-CoA + 2NADPH + 2H+ > mevalonate + 561 
2NADP+ + CoA-SH). In this assay, the decrease in absorbance at 340 nm, which represents 562 
the oxidation of NADPH by the catalytic subunit of HMGCoAR in the presence of the substrate 563 
HMG-CoA, was measured spectrophotometrically. Data points represent averages ± SD of 564 
three independent experiments in triplicate. (*) p < 0.05, (**) p < 0.001, and (***) p < 0.0001 565 
versus control (C). 566 
 567 
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Figure 5. PeptideRanker score of potentially bioactive peptides vs. Total Protein Spectrum 568 
Intensity (TPSI) of parent proteins.  569 
  570 
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Table 1. Predicted bioactive peptides by PeptideRanker and BIOPEP.  
Protein Acc. N. Peptide sequence  TPSI x 106 Enzyme Scorea Potential bioactive peptidesb Biological functionsb 
A0A0C5ARZ4 SHLNWVCIFLGFHSFGLYI 67,6 Pep 0.94 GLY Regulating phospho inositol mechanism peptide 
     GF, IF, GL, HL, FG, LG, SF, LN, GLY, IFL ACE-inhibitor 
     HL, LY Antioxidative 
     
FL, WV, HL, GL, GF, HS, LN, NW, SF, SH, 
YI 
Dipeptidyl peptidase IV inhibitor 
A0A0C5ARQ8 QIQFEGFCRF 29,9 Pep 0.92 RF. GF, EG ACE-inhibitor 
     EG, GF, IQ, QF, QI Dipeptidyl peptidase IV inhibitor 
A0A0C5ARZ4 IPDKANLGFRFP 67,6 Pep 0.87 RF, FP, IP, GF, FR, LG, KA ACE-inhibitor 
     KA, IP, FP, FR, GF, NL  Dipeptidyl peptidase IV inhibitor 
A0A0C5B2L0 SSEKGMIATFCCITGLL 38,4 Cod 0.86 IA, GM, GL, KG, TG, EK, TF ACE inhibitor  
     LL Glucose uptake stimulating peptide  
     SE Stimulating vasoactive substance release  
     IA, EK, GL, AT, KG, MI, TF, TG Dipeptidyl peptidase IV inhibitor 
H9A8L3 IPWTQLSPIRCAAESWAHM 44,1 Pep 0.80 IR, LSP, IP, AA, TQ, AH, WA ACE inhibitor 
     AH, PWT, PW, IR  Antioxidative 
     IR Renin inhibitor 
     WA Activating ubiquitin-mediated proteolysis 
     
IP, SP, WA, AA, WT, AE, AH, ES, IR, PI, 
PW, QL, SW, TQ 
Dipeptidyl peptidase IV inhibitor 
C6KI62 PIGISDWNSLFWIVHP 41,9 Cod 0.79 LF, IG, GI, HP ACE inhibitor  
     IV  Glucose uptake stimulating peptide 
     HP, SL, WI, WN, GI, PI, VH  Dipeptidyl peptidase IV inhibitor 
A0A0C5APZ1 
LPDTHGEAHYSTCMLLAGILLK
MG 
40,2 Pep 0.78 
HY, LA, GI, AG, MG, HG, GE, EA, AH, IL, 
ST 
ACE inhibitor  
     II, IL Glucose uptake stimulating peptide 
     AH, LK Antioxidative 
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     LA Activating ubiquitin-mediated proteolysis 
  
   LA, LP, LL , AG, AH, GE, GI, HY, IL, MG, 
ML, TH, YS  
Dipeptidyl peptidase IV inhibitor 
A0A088MFF4 PGRVLSLFVTLTLGWPLY 69,9 Pep 0.74 PG Prolyl endopeptidase inhibitor 
     LY, LF, PL, GW, GR, LG, PG  ACE inhibitor  
     VL Glucose uptake stimulating peptide 
   
  
PG 
Peptide regulating the stomach mucosal membrane 
activity 
     LY, WPL Antioxidative 
     WP, SL, PL, GW, LT, PG, TL, VL, VT Dipeptidyl peptidase IV inhibitor 
A0A090CXP8 DIFNPRGG 359,0 Cod 0.74 PR, IF, GG  ACE inhibitor 
     NP, FN, GG, RG Dipeptidyl peptidase IV inhibitor 
A6P6W0 RIWGEKYFGKNFNRLVKVK 
63,0 Pep 
0.73 
RL, FGK, IW, VK, FG, GK, WG, GE, NF, 
KY, EK 
ACE inhibitor 
     LV Glucose uptake stimulating peptide 
     VKV, WG  Antioxidative 
  
   EK, WG, FN, GE, IW, KV, KY, LV, NF, NR, 
RI, RL, RL, VK, YF  
Dipeptidyl peptidase IV inhibitor 
A7IZZ1 VRFEPQFSYFRI 40,9 Pep 0.71 RF, FR, VR, SY, PQ, FEP ACE inhibitor 
     EP, VR, FR, PQ, QF, RI, SY, YF  Dipeptidyl peptidase IV inhibitor 
E5DL82 PRNSWISCNMRLNAITL 64,8 Cod 0.70 RL, PR, LN, AI  ACE inhibitor 
     WI, LN, MR, NA, NM, RL, RN, SW, TL Dipeptidyl peptidase IV inhibitor 
H9A1V5 NDVKKFIAGQVASFKRL 30,8 Cod 0.69 RL, VK, IA, KR, AG, GQ, SF, KF, FKR ACE inhibitor 
     GQ  Neuropeptide  
     KK  Bacterial permease ligand  
     KF Renin inhibitor  
  
   VA, GQ, IA, AG, AS, KF, KK, KR, ND, QV, 
RL, SF, VK 
Dipeptidyl peptidase IV inhibitor 
H9A8L2 SPIGGGPEQLVMFVVLKNGY 39,9 Cod 0.68 GP  Prolyl endopeptidase inhibitor  
     MF, GY, GP, IG, GG, NG ACE inhibitor 
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     GP Antithrombotic  
     VL, LV  Glucose uptake stimulating peptide  
  
   
GP 
Peptide regulating the stomach mucosal membrane 
activity  
     LK  Antioxidative peptide  
  
   GP, VV, SP, GG, GY, LV, MF, NG, PI, QL, 
VL, VM 
Dipeptidyl peptidase IV inhibitor 
H9A8L2 GAVLNIAECCLLPTSYPRKDD 39,9 
Pep 0.67 YPR, PR, YP, LLP, IA, GA, SY, IAE, LN, 
PT, AV, AVL 
ACE inhibitor 
     VL, LL  Glucose uptake stimulating peptide  
     KD  Antioxidative peptide  
  
   LP, LL, YP, GA, IA, AE, AV, LN, PT, RK, 
SY, TS, VL  
Dipeptidyl peptidase IV inhibitor 
A0A0E3TIL1 NPRENFLKCFSKHIPNNVA 31,9 Pep 0.66 PR, IP, NF, CF  ACE inhibitor 
     LK Antioxidative peptide  
  
   VA, IP, NP, FL, HI, KH, NF, NN, NV, PN, 
SK 
Dipeptidyl peptidase IV inhibitor 
E5DL82 LICILLFIGAVGKS 64,8 Cod 0.64 LF, VG, IG, GA, GK, LLF, AV, IL  ACE inhibitor 
     IL, LI, LL  Glucose uptake stimulating peptide  
     LL, GA, AV, IL, KS, LI, VG  Dipeptidyl peptidase IV inhibitor 
A0A0C5AUJ6 GPTPISALIHAATM 465,0 Pep 0.63 GP  Prolyl endopeptidase inhibitor  
     GP, AA, PT, TP, TP ACE inhibitor 
     LI  Glucose uptake stimulating peptide  
  
   
GP  
Peptide regulating the stomach mucosal membrane 
activity  
     GP, HA, TP, AL, AA, AT, IH, LI, PI, PT, TM Dipeptidyl peptidase IV inhibitor 
A6P6W0 GEKYFGKNFNRLVKVKT 63,0 Cod 0.63 RL, FGK, VK, FG, GK, GE, NF, KY, EK ACE inhibitor 
     LV Glucose uptake stimulating peptide  
     VKV Antioxidative  
  
   EK, FN, GE, KT, KV, KY, LV, NF, NR, RL, 
VK, YF  
Dipeptidyl peptidase IV inhibitor 
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a. From PeptideRanker 
b. From BIOPEP 
 
 
  
A0A0C5B2I8 ATGRIVCANCHLANKPVDIEVP 19,4 Cod 0.61 LA, VP, HL, GR, TG, NK, KP, IE, EV ACE inhibitor 
     IV Glucose uptake stimulating peptide  
     HL, KP Antioxidative  
     LA  Ubiquitin-mediated proteolysis activating peptide  
     LA, VP, KP, HL, AT, EV, PV, RI, TG, VD Dipeptidyl peptidase IV inhibitor 
H9A1V5 ALSKNSMVKKFNLSSIKYIG 30,8 Pep 0.61 VK, IG, KY, KF, IKY ACE inhibitor 
     KF  Renin inhibitor  
  
   AL, FN, KF, KK, KY, MV, NL, SI, SK, VK, 
YI  
Dipeptidyl peptidase IV inhibitor 
E5DKP2 YSIQKVFSAGRLVGGEKGPYSV 60,7 Tryp 0.60 GP  Prolyl endopeptidase inhibitor 
  
   RL, VF, GP, VG, AG, GR, KG, GE, GG, QK, 
EK, KGP, EKGP  
ACE inhibitor 
     LV  Glucose uptake stimulating peptide  
  
   
GP  
Peptide regulating the stomach mucosal membrane 
activity  
     GGE  Antioxidative  
  
   GP, EK, AG, GE, GG, IQ, KG, KV, LV, PY, 
RL, SI, SV, VF, VG, YS  
Dipeptidyl peptidase IV inhibitor 
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